Multicenter randomized clinical trial comparing Estracyt mono-therapy with combined androgen blockade therapy (CAB) in the treatment of advanced prostate cancer

Nishinihon Journal of Urology

Volumn 63, Issue 1, 2001, Pages 1-9

  Takenaka, I ^a   Soramoto, S ^a   Kagawa, S ^a   Kanayama, H O ^a   Yokoyama, M ^a   Shuin, T ^a   Morioka, M ^a   Sumiyoshi, Y ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Advanced prostate cancer; CAB; Estracyt; Randomized clinical trial

Indexed keywords

ANTIANDROGEN; ESTRAMUSTINE PHOSPHATE; GONADORELIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; MALE; MONOTHERAPY; MULTICENTER STUDY; PROSTATE CANCER; RANDOMIZATION; TREATMENT OUTCOME;

EID: 0035135513     PISSN: 00290726     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland
2. Experience in advanced prostatic cancer: Orchiectomy and flutamide versus orchiectomy and estramustine phosphate
3. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
4. A comparison of bilateral orchiectomy with or without flutamide in stage D2 prostate cancer (NCI INT-0105 SWOG/ECOG)
5. Estramustine-A nitrogen mustard/steroid with antimicrotubule activity
6. New concepts on the androgen sensitivity of prostate cancer
7. Hormone-refractory (D3) prostate cancer: Refining the concept
8. Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials